Abbott and Novo Nordisk have partnered to bring an integrated digital solution that will involve the sharing of insulin data to facilitate the better management of diabetes.
According to the World Health Organisation, the worldwide population living with diabetes reached 422 million in 2014 and the global prevalence among adults is thought to be at 8.5%. In 2016, diabetes was the direct cause of 1.6 million deaths globally.
As part of the non-exclusive alliance, dose data from Novo Nordisk durable connected pens will be integrated directly into the digital health tools that are compatible with Abbott FreeStyle Libre system.
These compatible tools are comprised of the FreeStyle LibreLink mobile app and the LibreView cloud-based system.
Novo Nordisk’s pens are pre-filled devices intended for insulin delivery. The company’s portfolio includes a variety of such insulin pens, including NovoPen 5 and NovoPen Echo.
In October last year, the company entered agreements with Roche, Glooko and Dexcom to allow future integration of its NovoPen 6 and NovoPen Echo Plus insulin pens with digital health solutions.
Abbott’s FreeStyle Libre is a personal continuous glucose monitoring (CGM) system approved by the US Food and Drug Administration (FDA) in September 2017.
The device reads the glucose levels via a long-lasting personal glucose sensor that can be self-applied.
The partners expect the integration of their products to allow health care professionals, caregivers and patients to view glucose and insulin data together and aid them in making more informed treatment decisions.
Abbott Diabetes Care senior vice-president Jared Watkin said: “People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake.
“By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life.”
The companies are not alone in their development of new technology for diabetes care. Other companies such as Dexcom and monitoring solutions provider LifeScan have also recently launched diabetes management tech including management apps and glucose monitors.
Furthermore, Abbott announced CE-Mark clearance of its Determine HBsAg 2 test to detect hepatitis B surface antigen. Claimed to be the most sensitive rapid diagnostic, the test can be used with serum, plasma or whole blood.
The test can be deployed at the point-of-care and is designed to detect hepatitis B virus in 15 minutes. It is currently available in Europe, Africa, Asia Pacific and Latin America.
Additional reporting by Charlotte Edwards.